|Articles|October 15, 2009

Listen to a preview of Drugs, Devices or Data - Which is Most Valuable? Webcast

Listen to a preview of Drugs, Devices or Data – Which is Most Valuable? Webcast

Download Adobe Flash PlayerRegister Free for the Webcast

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda

ByNicholas Jacobus

October 14th 2025

Challenges of Positioning an Ultra-Sensitive Platform

ByNicholas Jacobus,Shana Tetrault, PhD

October 9th 2025

Translating Complex Scientific Findings into Actionable Insights

ByNicholas Jacobus,Shana Tetrault, PhD

October 8th 2025

More Than an Algorithm: Building Medical AI

ByAnna Vuolo

October 3rd 2025

AI and R&D: From the Eyes of an Entrepreneur

ByMichael Christel

October 2nd 2025

Listen to a preview of Drugs, Devices or Data - Which is Most Valuable? Webcast

Newsletter

Related Content

Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda

Challenges of Positioning an Ultra-Sensitive Platform

Translating Complex Scientific Findings into Actionable Insights

More Than an Algorithm: Building Medical AI

AI and R&D: From the Eyes of an Entrepreneur

Trending on PharmExec

Johnson and Johnson Reveals Plan to Separate Orthopaedics Business

The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.

The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma

Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda

Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil